Redeye leaves a comment following ExpreS2ion’s Phase I update for ES2B-C001, in which the company announced that all 19 planned patients hav...
Redeye comments on ExpreS2ion’s announcement of the outcome of the TO 13 warrant program.
Redeye comments on ExpreS2ion’s announcement that it has secured a guarantee undertaking of approximately SEK19.
Redeye provides a research update following the Q2 report recently published by ExpreS2ion.
Redeye leaves a brief comment following ExpreS2ion’s announcement of the third scheduled DSMB review of the Phase I trial with ES2B-C001.
Redeye provides a research update following the Q1 report recently published by ExpreS2ion.
Redeye leaves a comment following ExpreS2ion’s announcement of updated Phase I progress and refinements to the ES2B-C001 development strateg...
Redeye comments on the announced outcome of ExpreS2ion’s recent rights issue, which was subscribed to ~60% including guarantors and will pro...
Redeye comments on the recent phase Ia data from the Oxford-led BIO-002 study evaluating the RH5.
Redeye briefly comments on ExpreS2ion’s announcement of a published Hong Kong patent application covering glyco-engineering methods within t...
Redeye comments on ExpreS2ion’s finalized rights issue of approximately SEK53m, including free-of-charge TO13 warrants, aimed at funding com...
Redeye comments on ExpreS2ion’s updated Phase I immunogenicity data for ES2B-C001, showing HER2-specific antibody responses in eight of nine...
Redeye comments on ExpreS2ion’s announcement of a planned fully pre-emptive rights issue of approximately SEK53m, aimed at funding completio...
Redeye provides a research update following the Q4 report published by ExpreS2ion earlier today.
Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-targeting cancer vaccine candidate ES2B-C00...
Redeye initiates coverage of ExpreS2ion Biotech, a clinical-stage Scandinavian biotech company developing differentiated immunotherapies bas...
ExpreS2ion Biotechnologies driver en fas 1-studie med vaccinkandidaten ES2B-C001 på patienter med HER2-positiv bröstcancer.
ExpreS2ion Biotechnologies har ännu inte startat behandling med sitt vaccin i den fas 1-studie på bröstcancerpatienter som är bolagets främs...
ExpreS2ion Biotechnologies har påbörjat screening av deltagare i bolagets fas 1-studie med vaccinkandidaten ES2B-C001.
ExpreS2ion Biotechnologies har nått en viktig operativ milstolpe med godkännandet av bolagets fas 1-studie med bröstcancerpreparatet ES2B-C0...
ExpreS2ion Biotech har tagit ett steg närmare att inleda en first-in-human studie med sitt bröstcancervaccin ES2B-C001.
ExpreS2ion Biotechnologies gör framsteg i processen att inleda studier på människa med bröstcancervaccinen ES2B-C001.
ExpreS2ion Biotechnologies inriktar resurserna på att ansöka om godkännande för att inleda en fas 1-studie på människa, First-In-Human, unde...
Analysguiden räknar med att ExpreS2ion Biotechnologies får en utdelning på 22 MSEK från AdaptVac under 2024.
Långsammare rekrytering för ABNCoV2 fas 3-studie, utspädningseffekter samt lägre prognoser sänker motiverat värde.
Bolaget presenterar starka data och säkrar fas 3-studien men med bakgrund mot ett sjunkande antal covid-vaccinationer sänker Analysguiden si...
Bolaget gör justeringar gällande sin fas 3-studie med vaccinkandidaten ABNCoV2.
Bavarian Nordic kan inom kort starta fas 3-studie för påfyllnadsvaccinet ABNCoV2, vilket har stor potential.
Första resultat är presenterat från fas 2-studien med COVID-19 vaccinet ABNCoV2.
Presentation av första fas 2-data med COVID-19 vaccinet ABNCoV2 förväntas i december.
Första kliniska effektdata på COVID-19 vaccinet ABNCoV-2 gav lovande resultat.
